Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul 1;155(7):848-850.
doi: 10.1001/jamadermatol.2019.0063.

Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption

Kelsey Hirotsu  1 , Timothy M Dang, Shufeng Li, Joel W Neal  2 , Silvina Pugliese  1 , Aruna Subramanian  3 , Bernice Y Kwong  1
Affiliations

Association of Antibiotic Resistance With Antibiotic Use for Epidermal Growth Factor Receptor Inhibitor-Related Papulopustular Eruption

Kelsey Hirotsu et al. JAMA Dermatol. .

Abstract

This medical record review investigates whether use of topical clindamycin and/or oral tetracyclines during management of epidermal growth factor receptor (EGFR) inhibitor–related papulopustular eruption is associated with antibiotic-resistant bacterial infection.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Neal reported serving in a consulting or advisory role for ARIAD/Takeda, AstraZeneca, and Genentech/Roche and receiving research funding from Genentech/Roche, Merck & Co., Novartis, Boehringer Ingelheim, Exelixis, ARIAD/Takeda, and Nektar Therapeutics. Dr Kwong reported serving as a consultant to Genentech/Roche. No other disclosures were reported.

References

    1. Li T, Perez-Soler R. Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009;4(2):107-119. doi:10.1007/s11523-009-0114-0 - DOI - PubMed
    1. Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. ; MASCC Skin Toxicity Study Group . Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011;19(8):1079-1095. doi:10.1007/s00520-011-1197-6 - DOI - PMC - PubMed
    1. Eilers RE Jr, Gandhi M, Patel JD, et al. . Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010;102(1):47-53. doi:10.1093/jnci/djp439 - DOI - PubMed
    1. Common Terminology Criteria for Adverse Events v5.0 (CTCAE). https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs.... Accessed July 4, 2018
    1. Cunliffe WJ, Holland KT, Bojar R, Levy SF. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther. 2002;24(7):1117-1133. doi:10.1016/S0149-2918(02)80023-6 - DOI - PubMed

Publication types